320 related articles for article (PubMed ID: 17059165)
1. Novel tight binding PETT, HEPT and DABO-based non-nucleoside inhibitors of HIV-1 reverse transcriptase.
D'Cruz OJ; Uckun FM
J Enzyme Inhib Med Chem; 2006 Aug; 21(4):329-50. PubMed ID: 17059165
[TBL] [Abstract][Full Text] [Related]
2. Novel broad-spectrum thiourea non-nucleoside inhibitors for the prevention of mucosal HIV transmission.
D'Cruz OJ; Uckun FM
Curr HIV Res; 2006 Jul; 4(3):329-45. PubMed ID: 16842085
[TBL] [Abstract][Full Text] [Related]
3. The development of HEPT-type HIV non-nucleoside reverse transcriptase inhibitors and its implications for DABO family.
Chen W; Zhan P; Wu J; Li Z; Liu X
Curr Pharm Des; 2012; 18(27):4165-86. PubMed ID: 22621244
[TBL] [Abstract][Full Text] [Related]
4. Docking, molecular dynamics and quantitative structure-activity relationship studies for HEPTs and DABOs as HIV-1 reverse transcriptase inhibitors.
Mao Y; Li Y; Hao M; Zhang S; Ai C
J Mol Model; 2012 May; 18(5):2185-98. PubMed ID: 21947448
[TBL] [Abstract][Full Text] [Related]
5. Perspectives of non-nucleoside reverse transcriptase inhibitors (NNRTIs) in the therapy of HIV-1 infection.
De Clercq E
Farmaco; 1999; 54(1-2):26-45. PubMed ID: 10321027
[TBL] [Abstract][Full Text] [Related]
6. Structure-based drug design of non-nucleoside inhibitors for wild-type and drug-resistant HIV reverse transcriptase.
Mao C; Sudbeck EA; Venkatachalam TK; Uckun FM
Biochem Pharmacol; 2000 Nov; 60(9):1251-65. PubMed ID: 11008119
[TBL] [Abstract][Full Text] [Related]
7. Recent advances in the DABOs family as potent HIV-1 non-nucleoside reverse transcriptase inhibitors.
Yu M; Fan E; Wu J; Liu X
Curr Med Chem; 2011; 18(16):2376-85. PubMed ID: 21568919
[TBL] [Abstract][Full Text] [Related]
8. Application of Structure-based Methods to Analyze Resistance Mutations for Chemically Diverse Non-Nucleoside Reverse Transcriptase Inhibitors.
Tabassum T; Azeem SM; Muwonge AN; Frey KM
Curr HIV Res; 2020; 18(4):283-291. PubMed ID: 32493197
[TBL] [Abstract][Full Text] [Related]
9. Dawn of non-nucleoside inhibitor-based anti-HIV microbicides.
D'Cruz OJ; Uckun FM
J Antimicrob Chemother; 2006 Mar; 57(3):411-23. PubMed ID: 16431862
[TBL] [Abstract][Full Text] [Related]
10. Development of non-nucleoside reverse transcriptase inhibitors (NNRTIs): our past twenty years.
Zhuang C; Pannecouque C; De Clercq E; Chen F
Acta Pharm Sin B; 2020 Jun; 10(6):961-978. PubMed ID: 32642405
[TBL] [Abstract][Full Text] [Related]
11. The Lys103Asn mutation of HIV-1 RT: a novel mechanism of drug resistance.
Hsiou Y; Ding J; Das K; Clark AD; Boyer PL; Lewi P; Janssen PA; Kleim JP; Rösner M; Hughes SH; Arnold E
J Mol Biol; 2001 Jun; 309(2):437-45. PubMed ID: 11371163
[TBL] [Abstract][Full Text] [Related]
12. Hologram quantitative structure-activity relationships investigations of non-nucleoside reverse transcriptase inhibitors.
Pungpo P; Hannongbua S; Wolschann P
Curr Med Chem; 2003 Sep; 10(17):1661-77. PubMed ID: 12871115
[TBL] [Abstract][Full Text] [Related]
13. HEPT derivatives as non-nucleoside inhibitors of HIV-1 reverse transcriptase: QSAR studies agree with the crystal structures.
Gaudio AC; Montanari CA
J Comput Aided Mol Des; 2002 Apr; 16(4):287-95. PubMed ID: 12400858
[TBL] [Abstract][Full Text] [Related]
14. Non-nucleoside reverse transcriptase inhibitors (NNRTIs): past, present, and future.
De Clercq E
Chem Biodivers; 2004 Jan; 1(1):44-64. PubMed ID: 17191775
[TBL] [Abstract][Full Text] [Related]
15. Current status of the non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
Balzarini J
Curr Top Med Chem; 2004; 4(9):921-44. PubMed ID: 15134549
[TBL] [Abstract][Full Text] [Related]
16. Rational design and synthesis of phenethyl-5-bromopyridyl thiourea derivatives as potent non-nucleoside inhibitors of HIV reserve transcriptase.
Vig R; Mao C; Venkatachalam TK; Tuel-Ahlgren L; Sudbeck EA; Uckun FM
Bioorg Med Chem; 1998 Oct; 6(10):1789-97. PubMed ID: 9839009
[TBL] [Abstract][Full Text] [Related]
17. Discovery of novel benzimidazolones as potent non-nucleoside reverse transcriptase inhibitors active against wild-type and mutant HIV-1 strains.
Barreca ML; Rao A; De Luca L; Iraci N; Monforte AM; Maga G; De Clercq E; Pannecouque C; Balzarini J; Chimirri A
Bioorg Med Chem Lett; 2007 Apr; 17(7):1956-60. PubMed ID: 17276064
[TBL] [Abstract][Full Text] [Related]
18. Characteristics of a group of nonnucleoside reverse transcriptase inhibitors with structural diversity and potent anti-human immunodeficiency virus activity.
Yang SS; Fliakas-Boltz V; Bader JP; Buckheit RW
Leukemia; 1995 Oct; 9 Suppl 1():S75-85. PubMed ID: 7475321
[TBL] [Abstract][Full Text] [Related]
19. Structure-based design, synthesis, and biological evaluation of conformationally restricted novel 2-alkylthio-6-[1-(2,6-difluorophenyl)alkyl]-3,4-dihydro-5-alkylpyrimidin-4(3H)-ones as non-nucleoside inhibitors of HIV-1 reverse transcriptase.
Mai A; Sbardella G; Artico M; Ragno R; Massa S; Novellino E; Greco G; Lavecchia A; Musiu C; La Colla M; Murgioni C; La Colla P; Loddo R
J Med Chem; 2001 Aug; 44(16):2544-54. PubMed ID: 11472208
[TBL] [Abstract][Full Text] [Related]
20. Targeting the hydrophobic channel of NNIBP: discovery of novel 1,2,3-triazole-derived diarylpyrimidines as novel HIV-1 NNRTIs with high potency against wild-type and K103N mutant virus.
Zhou Z; Liu T; Wu G; Kang D; Fu Z; Wang Z; De Clercq E; Pannecouque C; Zhan P; Liu X
Org Biomol Chem; 2019 Mar; 17(12):3202-3217. PubMed ID: 30839042
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
